Initial testing of cisplatin by the pediatric preclinical testing program.

  title={Initial testing of cisplatin by the pediatric preclinical testing program.},
  author={Mimi Tajbakhsh and Peter James Houghton and C. Morton and Edward Anders Kolb and Richard Greg Gorlick and John M. Maris and Stephen T Keir and Jianrong Wu and C Patrick Reynolds and Malcolm A Smith and Richard B. Lock},
  journal={Pediatric blood & cancer},
  volume={50 5},
BACKGROUND Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. PROCEDURES Cisplatin was evaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC(50) concentration in vitro was determined for 96 hr exposure. Solid tumors were… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 11 extracted citations

Patient-Derived Mouse Models of Cancer

Molecular and Translational Medicine • 2017
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…